Completed PHASE3 NCT00033332

Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

A Randomized Phase III Trial Of Thalidomide (NSC # 66847) Plus Dexamethasone Versus Dexamethasone In Newly Diagnosed Multiple Myeloma

Sponsor: National Cancer Institute (NCI)

Conditions Multiple Myeloma and Plasma Cell Neoplasm

Interventions dexamethasone pamidronate disodium thalidomide zoledronic acid

Updated 6 times since 2017 Last updated: Apr 2, 2014 Started: Apr 30, 2002 Primary completion: Mar 31, 2006 Completion: Jun 30, 2006

Listed as NCT00033332, this PHASE3 trial focuses on Multiple Myeloma and Plasma Cell Neoplasm and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Atlanta, United States , Baltimore, United States , Bettendorf, United States , Boston, United States , Brooklyn, United States , Cedar Rapids, United States , Chicago, United States , Cleveland, United States , Columbus, United States and 48 more locations